![NA masthead new 1](https://prodcraftsa01.blob.core.windows.net/assets/products/neurology-alert/_contentImage/NA_masthead_new_1.png)
Neurology Alert – July 1, 2011
July 1, 2011
View Issues
-
Bacterial Meningitis: Rarer, in Older Patients, but Equally Deadly
With the advent of new vaccines, the incidence of bacterial meningitis has declined, particularly in children, but the mortality rate has remained the same. -
Variant Creutzfeldt-Jakob Disease: A Review of 150 Cases
Variant Creutzfeldt-Jakob disease usually presents with subtle psychiatric symptoms and there is usually a significant delay in diagnosis. -
REM Sleep Behavior Disorder and Biomarkers of Neurodegenerative Disease
Biomarkers for Parkinson's disease and related neurodegenerative diseases occur frequently in patients with idiopathic REM sleep behavior disorder. These include impairment of olfactory and color discrimination, and abnormalities in cerebral blood flow. -
Common Entrapment Neuropathies and Chronic Inflammatory Demyelinating Neuropathy
Entrapment neuropathies are not more common in the setting of chronic inflammatory demyelinating neuropathy and suggest a surgically treatable lesion. -
Are We Close to Understanding the Role of Fingolimod in the Treatment of MS?
Patients originally on interferon beta-1a in the TRANSFORMS study were re-randomized to either 0.5 or 1.25 mg of fingolimod. There was a reduction in relapse rate and MRI activity in patients that switched to fingolimod without an increase in severe adverse events. -
Stroke Alert: A Review of Current Clinical Stroke Literature
Crest failed to demonstrate any significant differ-ence in the primary endpoint (composite of stroke, myocardial infarction, or death during the 4-year follow-up period) between carotid artery stenting (CAS) and carotid endarterectomy (CEA) in patients with symptomatic or asymptomatic carotid artery stenosis. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.